Published in J Clin Pharmacol on June 10, 2013
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood (2015) 1.49
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol (2016) 0.82
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 3.25
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 3.21
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol (2010) 2.67
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem (2010) 2.06
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res (2010) 1.81
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res (2011) 1.67
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther (1993) 1.45
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res (2002) 1.42
Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev (2003) 1.41
CD30 in normal and neoplastic cells. Clin Immunol (1999) 1.29
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood (2007) 1.29
Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther (2010) 1.12
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol (2001) 1.08
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol (2007) 0.96
Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol (2007) 0.90
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet (2012) 4.41
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol (2011) 2.40
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res (2008) 2.38
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer (2003) 2.21
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol (2011) 2.19
Contralesional repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. Lancet Neurol (2008) 2.10
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
Multimodal imaging of brain reorganization in motor areas of the contralesional hemisphere of well recovered patients after capsular stroke. Brain (2005) 2.03
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci U S A (2011) 1.95
The mechanisms of interhemispheric inhibition in the human motor cortex. J Physiol (2002) 1.92
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Constraint-induced therapy in stroke: magnetic-stimulation motor maps and cerebral activation. Neurorehabil Neural Repair (2003) 1.83
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res (2010) 1.81
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol (2011) 1.70
Effect of low-frequency repetitive transcranial magnetic stimulation on interhemispheric inhibition. J Neurophysiol (2005) 1.70
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem (2006) 1.68
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood (2012) 1.67
Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol (2002) 1.67
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood (2009) 1.66
Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. Am J Respir Crit Care Med (2012) 1.64
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood (2012) 1.64
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma (2008) 1.63
Exploring the connectivity between the cerebellum and motor cortex in humans. J Physiol (2004) 1.60
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood (2013) 1.59
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci (2012) 1.49
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep (2002) 1.48
Myoclonus. Continuum (Minneap Minn) (2013) 1.47
Increased motor cortical facilitation and decreased inhibition in Parkinson disease. Neurology (2013) 1.47
Somatosensory evoked potentials recorded from the human pedunculopontine nucleus region. Mov Disord (2010) 1.46
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood (2008) 1.45
Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs (2002) 1.45
Effective treatment of mouse sepsis with an inhibitory antibody targeting integrin αvβ5. Crit Care Med (2013) 1.44
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (2011) 1.44
Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) (2016) 1.43
Engraftment is optimal when myoblasts are transplanted early: the role of hepatocyte growth factor. Ann Thorac Surg (2010) 1.42
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.40
Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
Two phases of short-interval intracortical inhibition. Exp Brain Res (2003) 1.37
Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel (2006) 1.29
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem (2005) 1.28
Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma (2010) 1.28
Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve (2006) 1.27
The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. Mov Disord (2011) 1.27
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol (2004) 1.26
Digit somatotopy within cortical areas of the postcentral gyrus in humans. Cereb Cortex (2008) 1.26
Rapid modulation of GABA in sensorimotor cortex induced by acute deafferentation. Ann Neurol (2002) 1.25
FTSite: high accuracy detection of ligand binding sites on unbound protein structures. Bioinformatics (2011) 1.25
Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex (2007) 1.24
Effects of theta burst stimulation on motor cortex excitability in Parkinson's disease. Clin Neurophysiol (2011) 1.23
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood (2011) 1.22
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol (2005) 1.22
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol (2007) 1.20
Effect of transcranial magnetic stimulation on Parkinson motor function--systematic review of controlled clinical trials. Mov Disord (2009) 1.20
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol (2014) 1.18
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage (2002) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Cathepsin cleavage of sirtuin 1 in endothelial progenitor cells mediates stress-induced premature senescence. Am J Pathol (2012) 1.16
Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol (2010) 1.16